Skip to main content

ScholarsBetaWeill Cornell Medicine

Browse About Sign in

Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Loading search results…

Browse

Scholars8,803 Publications201,348 Funding7,268 Clinical research5

FiltersClear all

Status

Recruiting2
Active, not recruiting1
Completed2

Study type

Interventional5

Phase

Phase 25
Not applicable4
Not reported3
Phase 31
Phase 41

Investigator

Tracy A. Butler2
Anna Starikovsky Nordvig1
Anthony O. Ahmed1
Faith Gunning1

Department

Psychiatry2
Radiology2
Neurology1

Condition

Cognitive Dysfunction5
Carcinoma, Non-Small-Cell Lung11
Colitis, Ulcerative11
Prostatic Neoplasms11
Neoplasms9

Intervention type

Drug4
Device2

Sponsor type

WCM (investigator-initiated)4
Industry1

Start date

to

Has results posted1

Phase 2×Cognitive Dysfunction×Clear all

Showing 1–5 of 5 studiesSort:

Active, not recruitingInterventional · Phase 2NCT06223360 ↗
A Seamless Phase 2A-Phase 2B Randomized Double-Blind Placebo- Controlled Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

Show all 50

Show fewer

Anna Starikovsky NordvigPI

Intervention: Drug: Low Dose Benfotiamine · Drug: High Dose Benfotiamine · Drug: Placebo
Dates: Mar 2024 – Dec 2027 (est.)
Sponsor: Winifred Masterson Burke Medical Research

Alzheimer Disease

RecruitingInterventional · Phase 2NCT06502964 ↗

Double-Blind, Placebo-Controlled Study of ALTO-101 in Patients With Schizophrenia and Cognitive Impairment

Anthony O. AhmedPI

Intervention: Drug: ALTO-101 · Device: ALTO-101 Transdermal Delivery System · Drug: Placebo · Device: Placebo Transdermal Delivery System
Dates: Jun 2024 – Feb 2026 (est.)
Sponsor: Alto Neuroscience

SchizophreniaCognitive Impairment

RecruitingInterventional · Phase 2NCT07553338 ↗

Safety Assessment of Leronlimab and Its Effect on Neuroinflammation Targets in Alzheimer's Disease

Tracy A. ButlerPI

Intervention: Drug: Leronlimab (700mg)
Dates: Apr 2026 – Nov 2027 (est.)
Sponsor: Weill Medical College of Cornell University

Mild Cognitive Impairment (MCI) Due to Alzheimer's DiseaseAlzheimer's Disease

CompletedInterventional · Phase 2NCT03649724 ↗

The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's

Tracy A. ButlerPI

Intervention: Drug: Placebo · Drug: Eligard 22.5Mg Suspension for Injection
Dates: Nov 2020 – Jul 2026
Sponsor: Weill Medical College of Cornell University

Alzheimer DiseaseMild Cognitive Impairment

CompletedInterventional · Phase 2NCT04843930 ↗

Improving Cognitive Health in COVID-19 Survivors Through Digital Therapeutics

Faith GunningPI

Intervention: Device: AKL-T01
Dates: Jul 2021 – Feb 2023· Results posted
Sponsor: Weill Medical College of Cornell University

Cognitive DysfunctionCovid19